Publications by authors named "M Rekart"
Background: Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.
View Article and Find Full Text PDFBackground: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for INH-resistant, RIF-susceptible TB (HR-TB). Uzbekistan has a high burden of TB (62/100,000 population) and multidrug-resistant TB (12/100,000 population).
View Article and Find Full Text PDFTajikistan has a high burden of rifampicin-resistant TB (RR-TB), with 2,700 new cases estimated for 2021 (28/100,000 population). TB is spread among household members through close interaction and children exposed through household contact progress to disease rapidly and frequently. We retrospectively analysed programmatic data from household contact tracing in Dushanbe over 50 months.
View Article and Find Full Text PDFBedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for BDQ-resistant TB.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effectiveness of the Xpert MTB/RIF Ultra assay in detecting tuberculosis (TB) in fresh stool samples from children under 15 years old in Dushanbe, Tajikistan, enrolling 688 participants from April 2019 to October 2021.
- The assay showed a sensitivity of 68.8% and a high specificity of 98.7%, indicating it can effectively identify TB in this population, despite challenges like staffing shortages and outdated protocols due to COVID-19.
- This report, being one of the first from Central Asia and a low-middle-income country, supports the WHO's recommendation to use fresh stool as an acceptable sample for TB testing in young children, who struggle to provide sputum samples.